全文获取类型
收费全文 | 3782篇 |
免费 | 475篇 |
国内免费 | 112篇 |
专业分类
耳鼻咽喉 | 35篇 |
儿科学 | 27篇 |
妇产科学 | 81篇 |
基础医学 | 427篇 |
口腔科学 | 23篇 |
临床医学 | 172篇 |
内科学 | 263篇 |
皮肤病学 | 38篇 |
神经病学 | 69篇 |
特种医学 | 33篇 |
外国民族医学 | 6篇 |
外科学 | 472篇 |
综合类 | 398篇 |
预防医学 | 245篇 |
眼科学 | 16篇 |
药学 | 472篇 |
3篇 | |
中国医学 | 233篇 |
肿瘤学 | 1356篇 |
出版年
2024年 | 9篇 |
2023年 | 52篇 |
2022年 | 141篇 |
2021年 | 143篇 |
2020年 | 194篇 |
2019年 | 140篇 |
2018年 | 157篇 |
2017年 | 154篇 |
2016年 | 162篇 |
2015年 | 168篇 |
2014年 | 203篇 |
2013年 | 365篇 |
2012年 | 209篇 |
2011年 | 215篇 |
2010年 | 188篇 |
2009年 | 195篇 |
2008年 | 176篇 |
2007年 | 176篇 |
2006年 | 172篇 |
2005年 | 135篇 |
2004年 | 121篇 |
2003年 | 105篇 |
2002年 | 86篇 |
2001年 | 95篇 |
2000年 | 86篇 |
1999年 | 58篇 |
1998年 | 48篇 |
1997年 | 46篇 |
1996年 | 43篇 |
1995年 | 34篇 |
1994年 | 31篇 |
1993年 | 15篇 |
1992年 | 19篇 |
1991年 | 16篇 |
1990年 | 15篇 |
1989年 | 17篇 |
1988年 | 12篇 |
1987年 | 12篇 |
1986年 | 12篇 |
1985年 | 23篇 |
1984年 | 21篇 |
1983年 | 21篇 |
1982年 | 18篇 |
1981年 | 19篇 |
1980年 | 13篇 |
1979年 | 11篇 |
1978年 | 8篇 |
1977年 | 5篇 |
1975年 | 2篇 |
1972年 | 1篇 |
排序方式: 共有4369条查询结果,搜索用时 15 毫秒
1.
《Vaccine》2020,38(39):6141-6152
Influenza vaccination is considered the most valuable means to prevent and control seasonal influenza infections, which causes various clinical symptoms, ranging from mild cough and fever to even death. Among various influenza vaccine types, the inactivated subunit type is known to provide improved safety with reduced reactogenicity. However, there are some drawbacks associated with inactivated subunit type vaccines, with the main ones being its low immunogenicity and the induction of Th2-biased immune responses. In this study, we investigated the role of a single-stranded RNA (ssRNA) derived from the intergenic region in the internal ribosome entry site of the Cricket paralysis virus as an adjuvant rather than the universal vaccine for a seasonal inactivated subunit influenza vaccine. The ssRNA adjuvant stimulated not only well-balanced cellular (indicated by IgG2a, IFN-γ, IL-2, and TNF-α) and humoral (indicated by IgG1 and IL-4) immune responses but also a mucosal immune response (indicated by IgA), a key protector against respiratory virus infections. It also increases the HI titer, the surrogate marker of influenza vaccine efficacy. Furthermore, ssRNA adjuvant confers cross-protective immune responses against heterologous influenza virus infection while promoting enhanced viral clearance. Moreover, ssRNA adjuvant increases the number of memory CD4+ and CD8+ T cells, which can be expected to induce long-term immune responses. Therefore, this ssRNA-adjuvanted seasonal inactivated subunit influenza vaccine might be the best influenza vaccine generating robust humoral and cellular immune responses and conferring cross-protective and long-term immunity. 相似文献
2.
YS Nagar S Singh V Sawlani L Pal K Dimri P Lal 《Journal of Medical Imaging and Radiation Oncology》2005,49(2):160-162
A rare case of an advanced primary broad ligament carcinoma is discussed, with a review of the literature regarding its incidence, presentation and management. This patient showed a complete response to adjuvant cisplatin-based chemotherapy following panhysterectomy and is presently without any evidence of disease, 15 months after completion of her treatment. 相似文献
3.
The aim was to determine whether the immunogenicity of an investigational hepatitis B vaccine (spHB) is at least as high as that of a licensed control vaccine, Engerix B®, and to evaluate its safety before inclusion in new pediatric combination vaccines. Two randomized, controlled, blind-observer, Phase 3 trials were performed: one in Argentina (344 participants aged 10–15 years, 10 μg HBsAg/dose) and one in Uruguay (344 participants aged 16–45 years, 20 μg HBsAg/dose). Both vaccines were given in a 0, 1, 6 month schedule to all participants with a baseline anti-Hep B antibody titer <0.6 mIU/mL. Antibody titers were measured pre-dose 1, 1 month after dose 2, pre-dose 3, and 1 month after dose 3. Statistical non-inferiority analyses were performed on seroprotection rates (SP) post-dose 3 (% with anti-Hep B titers ≥10 mIU/mL; delta non-inferiority limit of −10%). In both studies, SP for the spHB vaccine was 100% and the spHB vaccine was non-inferior in terms of SP to the licensed control vaccine. GMTs post-dose 3 were approximately 1.8- and 4.1-fold higher for spHB in the 10–15 year and 16–45 year age groups, respectively. Reactogenicity was low for each vaccine, after each dose. This highly immunogenic hepatitis B candidate vaccine was selected for further investigation as a component of new pediatric combination vaccines. 相似文献
4.
R.J.W. de Keizer 《International ophthalmology》1997,21(6):335-341
In a prospective study the results of a pterygium excision in 54 patients (57 eyes) who underwent a superficial free conjunctival
autograft (FCG) were compared to those of patients who were treated with postoperative90Sr-irradiation. In 51 cases the minimum
follow-up was six months, the maximum follow-up seven years. We divided the study up into a randomized part and an open part.
In the randomized part, surgery of a primary pterygium was performed in 25 eyes, of which 16 were treated with a FCG and compared
with 9 eyes with primary pterygium surgery and postoperative90Sr beta-irradiation. In the same period 16eyes were treated
because of a recurrent pterygium: 8 with FCG and 8 with90Sr-irradiation. In the open part of the study16 eyes with primary
pterygium were successively treated with FCG alone.
The results showed in the randomized, as well as in the open study on primary surgery with a minimum follow-up of six month,
one recurrence in each of the FCG-groups (2 out of 31 eyes =6.4%), and no recurrences in the 90Sr-group(0%). In the randomized
group of patients treated for a recurrent pterygium one recurrence developed in the FCG group (1 out of 8 eyes =12.5%) and
one in the 90Sr-group (1 out of 7 =14.6%). Analysis of other clinical parameters showed that postoperative treatment with
corticosteroids, nonsteroidal anti-inflammatory drugs, and artificial tears was necessary for a longer period in the FCG group
than in the90Sr-group.
This revised version was published online in August 2006 with corrections to the Cover Date. 相似文献
5.
免疫抑制因子对佐剂关节炎的影响 总被引:1,自引:0,他引:1
目的;研究免疫抑制因子对佐剂关节炎发病的影响。方法:检测对照组与实验组对正常小鼠淋巴细胞转化的影响。结果:脑室注射IL1的关节炎大鼠在第0、7、14、28、35d的血清具有明显的抑制淋巴细胞转移化的作用。关节炎症状加重,病程延长。结论:免疫抑制蛋白可能参与佐剂关节炎的发病,有可能是造成关节炎的原因之一。 相似文献
6.
Franco Rilke M. D. F. R. C. Umberto Veronesi M. D. Alberto Luini M. D. Cristina Brambilla M. D. Viviana Galimberti M. D. Stefano Zurrida M. D. Silvana Pilotti M. D. M. I. A. C. Silvana Di Palma M. D. Roberto Zucali M. D. Laura Lozza M. D. 《The breast journal》1996,2(3):176-180
Abstract: Breast conservation surgery is an effective and safe treatment for many breast carcinomas. It may be possible to further limit the extent of resection (or expand the indication for breast conservation) by the application of preoperative chemotherapy and radiotherapy. We explored the feasibility of this in a pilot study.
Seventy-three patients (mean age 48, 63% premenopausal) with confirmed breast cancer, less than 2.5 cm, received chemotherapy (Group A) or chemotherapy plus radiotherapy (Group B) prior to limited resection (tumorectomy). Axillary dissection was always performed. Results: In 6/31 (19%) Group A and 17/42 (40%) Group B patients the tumor was not palpable after preoperative treatment, with complete pathological remission in 1 and 3 cases respectively. Histologic grading, mitosis, cellular alteration, and cellularity evaluations indicated a consistently greater therapeutic effect with chemoradiotherapy than with chemotherapy alone.
In conclusion, radiotherapy appears useful in the preoperative treatment of breast cancer and its use in association with various drug combinations should be further explored. 相似文献
Seventy-three patients (mean age 48, 63% premenopausal) with confirmed breast cancer, less than 2.5 cm, received chemotherapy (Group A) or chemotherapy plus radiotherapy (Group B) prior to limited resection (tumorectomy). Axillary dissection was always performed. Results: In 6/31 (19%) Group A and 17/42 (40%) Group B patients the tumor was not palpable after preoperative treatment, with complete pathological remission in 1 and 3 cases respectively. Histologic grading, mitosis, cellular alteration, and cellularity evaluations indicated a consistently greater therapeutic effect with chemoradiotherapy than with chemotherapy alone.
In conclusion, radiotherapy appears useful in the preoperative treatment of breast cancer and its use in association with various drug combinations should be further explored. 相似文献
7.
(张明敏)(刘沛霖)(叶望云)EffectofTripterygiumVilfordiionAdrenalCortexinRatwithAdjuvantArthritis¥ZHANGMing-min;LIUPei-lin;YEWang-yun(Tongji... 相似文献
8.
Abstract: The optimal timing of systemic cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy and local radiation in adjuvant breast cancer has been a debatable subject. To evaluate the Lankenau Hospital experience with sequential CMF chemotherapy followed by radiation in the adjuvant therapy of stage I and stage II breast cancer we reviewed the records of patients at our center. This group of 34 patients was treated in a homogenous manner, all receiving standard CMF for six cycles followed by radiotherapy after lumpectomy with axillary lymph node dissection. The radiation course was 5040cGy to the entire breast (28 fractions in 45 elapsed days) followed by a boost to the tumor site of 1800cGy in 10 fractions. Thirty-four patients were identified and followed for an average of 5 years (range 1.5–11.5 years). One patient had local recurrence and with subsequent treatment is disease-free at 5 years postrecurrence (8 years from initial diagnosis). Two deaths were not breast-cancer related (1 myocardial infarction at year 3, 1 melanoma at year 7.5). The estimated probability of no relapse at 5 years and 8 years by Kaplan-Meier analysis is 79% and 60% respectively. Overall and disease-free survival in this group of patients treated with breast-conserving surgery and CMF chemotherapy followed by radiation is excellent. There appears to be no detriment to delaying radiotherapy until full doses of systemic treatment are given as local recurrence was rare (6%) and was amenable to further treatment. 相似文献
9.
Nonstereospecific studies have indicated that the pharmacokinetics of propranolol (PR) are altered in inflammatory conditions such as arthritis. However, as the kinetics and dynamics of PR are stereoselective, we examined the effect of adjuvant arthritis (AA) on the disposition of the individual enantiomers. A novel normal-phase stereospecific HPLC assay for PR was developed involving chiral derivatization with S-(naphthyl)ethyl isocyanate and fluorescence detection. Oral and iv doses of racemic PR were administered to control and AA rats (n = 6). AA had no significant effect on either clearance or S:R ratio after iv doses. On the other hand, after oral doses, clearance was significantly decreased in AA. Although significant for both enantiomers, this effect was more pronounced on the less active R-enantiomer. The AUC R:S ratio was, therefore, significantly altered (AA, 14 ± 3.0; control, 4.3 ± 1.2). Increased total (S + R) plasma concentrations of PR in AA, possibly due to a reduced intrinsic clearance, therefore, reflect mainly increased concentrations of the less active R-enantiomer. 相似文献
10.
尼美舒利(Nime)0.6、30、15mg·kg^-1对佐剂性关节炎大鼠的原发性和继发性炎症反应均有明显的抑制作用,用药组继发性炎痘反应的全身症状也明显减轻,而Nime对佐剂性关节炎大鼠低下的脾细胞增殖反应和腹腔巨噬细胞产生过高的IL-1活性却无明显影响,提示Nime无明显的免疫作用,该结果表明,Nime对佐剂性关节炎大鼠有明显的治疗作用,这一作用可能与Nime有较强的抗炎作甩有关。 相似文献